Further reading

Bromidge, S. M., et al. (1997) 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): The first selective and brain penetrant 5-HT2C receptor antagonist. Journal of Medicinal Chemistry, 40, 3494-3496 [DOI: 10.1021/jm970424c] [PubMed: 9357513].

Bromidge, S. M., Dabbs, S., Davies, D. T., et al. (1998) Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. Journal of Medicinal Chemistry, 41, 1598-1612 [DOI: 10.1021/jm970741j] [PubMed: 9572885].

Bromidge, S. M., Dabbs, S., Davies, D. T., et al. (1999) Model studies on a synthetically facile series of N-substituted phenyl-N-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl)indolines that are potent and selective 5-HT2C/2B receptor antagonists. Bioorganic and Medicinal Chemistry, 7, 2767-2773 [DOI: 10.1016/S0968-0896(99)00228-X] [PubMed: 10658582].

Bromidge, S. M., Dabbs, S., Davies, D. T., et al. (2000) Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB 243213) as a potential antidepressant/anxiolytic agent. Journal of Medicinal Chemistry, 43, 1123-1134 [DOI: 10.1021/jm990388c] [PubMed: 10737744].